Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 13Phase 1 4Phase NA 2Phase 2/3 2Phase 4 1Phase 1/2 1

Status

Unknown 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × aumolertinib × Thoracic × Clear all
NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05826483 2023-04-24

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
20 enrolled
Thoracic

Lung Neoplasms

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
174 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
42 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡